引用文本：翟晓慧. 2025年美国临床肿瘤学会年会结直肠癌治疗进展[J/CD]. 消化肿瘤杂志（电子版）, 2025, 17(3):316-318.

作者：翟晓慧

单位：中山大学附属第六医院肿瘤内科，广东 广州 510000

Author：Zhai Xiaohui

Unit：Department of Oncology, the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510000, Guangdong, China

摘要：

结直肠癌是全球发病率排名第三、死亡率排名第二的恶性肿瘤。其主要分为两大类，错配修复缺陷（deficient mismatch repair, dMMR）/高微卫星不稳定（microsatellite instability-high, MSI-H）结直肠癌和微卫星稳定（microsatellite stability, MSS）结直肠癌。dMMR/MSI-H结直肠癌的治疗主要以免疫治疗为主，预后相对较好。MSS结直肠癌主要以靶向治疗联合化疗为主，预后相对较差。围绕结直肠癌的治疗，每年都有新的研究报道以及治疗方案的更新。本文将总结2025年美国临床肿瘤学会年会上有关结直肠癌治疗的研究进展，为临床提供参考。

关键词：美国临床肿瘤学会年会；结直肠癌；治疗进展

Abstract：

Colorectal cancer is a common malignant tumor that ranks third in morbidity and second in mortality globally. It is classified into two major subtypes: deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer and microsatellite stable (MSS) colorectal cancer. The treatment of dMMR/MSI-H colorectal cancer predominantly involves immunotherapy and is associated with a relatively favorable prognosis. In contrast, MSS colorectal cancer is mainly treated with targeted therapy combined with chemotherapy and carries a relatively poorer prognosis. New research findings and updates to treatment guidelines for colorectal cancer are reported annually. This article summarizes the advances in the treatment of colorectal cancer presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting, aiming to provide insights for clinical practice.

Key words：American Society of Clinical Oncology annual meeting; Colorectal cancer; Treatment advances

注：网络优先发布